Patents by Inventor Sandra Brahimi

Sandra Brahimi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12740931
    Abstract: A composition is described, comprising or consisting of chrysin, rosmarinic acid, at least one peptide or derivative thereof, having a sequence of 4 to 10 amino acids comprising the active sequence GQPR and a physiologically acceptable medium. A derivative corresponds to the active sequence GQPR modified at the N-terminal end with an acyl (—CO—R1), sulfonyl (—SO2-R1) group or a biotinoyl group and/or at the C-terminal end with an OR1, NH2, NHR1 group or NR1R2, R1 and R2 being as defined herein and where the composition acts on the effects of light radiation on the skin and/or of its appendages, and more particularly the effects of blue light to fight against harmful effects and in a particularly advantageous manner at the same time to increase the beneficial effects by resynchronizing the circadian cycle.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: September 22, 2026
    Assignee: Sederma
    Inventors: Philippe Mondon, Thibault Marchand, Sandra Brahimi, Emmanuel Doridot
  • Publication number: 20230026167
    Abstract: A composition is described, comprising or consisting of chrysin, rosmarinic acid, at least one peptide or derivative thereof, having a sequence of 4 to 10 amino acids comprising the active sequence GQPR and a physiologically acceptable medium. A derivative corresponds to said peptide modified at the N-terminal end with an acyl (—CO—R1), sulfonyl (—SO2—R1) group or a biotinoyl group and/or at the C-terminal end with an OR1, NH2, NHR1 group or NR1R2, R1 and R2 being as defined herein and where the composition acts on the effects of light radiation on the skin and/or of its appendages, and more particularly the effects of blue light to fight against harmful effects and in a particularly advantageous manner at the same time to increase the beneficial effects by resynchronizing the circadian cycle.
    Type: Application
    Filed: December 14, 2020
    Publication date: January 26, 2023
    Applicant: Sederma
    Inventors: Philippe Mondon, Thibault Marchand, Sandra Brahimi